KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $387.1 million.

  • Resmed's Operating Expenses rose 1587.63% to $387.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year increase of 1143.75%. This contributed to the annual value of $1.4 billion for FY2025, which is 256.08% up from last year.
  • As of Q4 2025, Resmed's Operating Expenses stood at $387.1 million, which was up 1587.63% from $374.3 million recorded in Q3 2025.
  • In the past 5 years, Resmed's Operating Expenses ranged from a high of $387.1 million in Q4 2025 and a low of $223.8 million during Q1 2021
  • In the last 5 years, Resmed's Operating Expenses had a median value of $317.6 million in 2023 and averaged $309.4 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 2808.18% in 2023, then plummeted by 1016.78% in 2024.
  • Quarter analysis of 5 years shows Resmed's Operating Expenses stood at $255.6 million in 2021, then increased by 17.18% to $299.5 million in 2022, then increased by 24.14% to $371.8 million in 2023, then dropped by 10.17% to $334.0 million in 2024, then grew by 15.88% to $387.1 million in 2025.
  • Its Operating Expenses stands at $387.1 million for Q4 2025, versus $374.3 million for Q3 2025 and $365.5 million for Q2 2025.